NCT06939647

An Expanded Access Study to Assess Treprostinil Palmitil Inhalation Powder (TPIP) for Participants With Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)

Treprostinil Palmitil Inhalation Powder (TPIP) in Patients With Pulmonary Arterial Hypertension or Pulmonary Hypertension Associated With Interstitial Lung Disease

• Status: Available
• Phase: —
• Study type: Expanded Access
• Enrollment: —
• Sponsor: Insmed Incorporated · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: —

Summary

The purpose of this study is to provide continued access to TPIP for participants who have successfully completed the open-label extension (OLE) studies of INS1009-203 for PAH or INS1009-212 for PH-ILD.

Detailed description

Participants will receive TPIP 80 micrograms (μg), 160 μg, or 320 μg, inhalation single-dose capsules, orally, once daily (QD).

Conditions

• Pulmonary Arterial Hypertension
• Pulmonary Hypertension, Interstitial Lung Disease

Interventions

Type	Name	Description
DRUG	Treprostinil Palmitil	Treprostinil Palmitil Inhalation Powder

Timeline

• First posted: 2025-04-23
• Last updated: 2026-02-27